Previous close | 0.3700 |
Open | 0.3700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.3700 - 0.3700 |
52-week range | 0.3700 - 0.4200 |
Volume | |
Avg. volume | 177 |
Market cap | 25.546M |
Beta (5Y monthly) | 1.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS, April 04, 2024--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
PARIS & BOSTON, April 02, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the opening of the first Italian Center of Excellence for the use of Cellvizio to identify and treat food intolerances in adult patients suffering from Irritable Bowel Syndrome (IBS). The Cellvizio Food Intolerance Test (C-FIT) is now performed by Dr. Al
PARIS & BOSTON & LONDON, March 27, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and V7, a leading AI and data labeling company, today announced their partnership to develop a cutting-edge infrastructure for AI applications with Cellvizio.